FDA rejects Sandoz's Neulasta copy, giving Amgen a break from the biosim onslaught

Amgen’s ($AMGN) aging superstars have been under assault lately by Novartis’ ($NVS) Sandoz unit and its biosimilars ambitions. But the Big Biotech scored a break at the hands of regulators: The FDA rebuffed Sandoz's biosim version of Amgen's blockbuster Neulasta, Novartis disclosed Tuesday.

Within its Q2 results, Novartis revealed that its Neulasta biosimilar candidate had been turned down by the FDA, which issued a complete response letter after accepting the company’s application last November.

“We are working with the agency to address remaining questions,” the Swiss pharma giant said, without providing details.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

It’s good news for Amgen, which has so far been the only victim of Sandoz’s biosimilar trailblazing in the U.S. Last year, Sandoz became the first to hit the U.S. market with a biosim--Zarxio, a copy of Amgen’s Neupogen--and it has also taken aim at the drugmaker’s anti-TNF giant Enbrel. An FDA advisory committee last week recommended that the agency green light Sandoz's copy in all of Enbrel’s approved indications.

Now, the California company has at least a bit more time to keep Neulasta’s blockbuster haul all to itself. Amgen’s No. 2 seller, behind Enbrel, Neulasta netted $4.72 billion in sales last year, with $3.89 billion of that coming in the U.S.

It’s not the first time the FDA has rejected an Amgen knockoff, either. Last October, regulators turned away Pfizer’s ($PFE) Hospira unit, which was seeking to pass muster with a biosimilar version of kidney disease drug Epogen.

And while the regulatory hurdles won’t keep biosimilars at bay forever, they’ll help keep Amgen’s top line stable while it pursues a biosimilar agenda of its own. It’s currently working to snag an OK for its copy of AbbVie’s ($ABBV) worldwide bestseller Humira, and last week that med scored backing from an FDA advisory panel.

- read the release

Special Report: Top 20 generics companies by 2014 revenue - Novartis - Sandoz

Related Articles:
Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen sales
In unanimous vote, FDA committee backs Amgen's Humira biosim
Novartis' Sandoz aims for 5 biosim launches by 2020
Novartis takes a third biosimilar shot at Amgen with a copy of the blockbuster Neulasta
Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?

Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.